Experimental Drug Extends Survival for Advanced Pancreatic Cancer

A new experimental pill, daraxonrasib, has shown a significant improvement in survival rates for patients with advanced pancreatic cancer. The drug targets KRAS mutations, a previously challenging target in cancer treatment, nearly doubling the median survival time. These promising findings were published in a peer-reviewed journal and presented at a major oncology meeting.